Review Article
Volume 13 Issue 10 - 2021
The Essentials in Tourette Syndrome
Sacristán HE1*, Galati AS2, Canestrari L3 and Gómez Forero AG3
1Department of Neurology, Anselmo Marini Rehabilitation Institut, Professor of Neurology, School of Medicine, University of Morón, Associate Professor of Neurology, School of Medicine, UBA, Buenos Aires, Argentina
2Department of Neurosurgery, Cosme Argerich Hospital, Department of Neurosurgery, Bernardo Houssay Hospital, Buenos Aires, Argentina
3Hospital Teaching Unit, Bernardo Houssay Hospital, Buenos Aires, Argentina
*Corresponding Author: Sacristán HE, Department of Neurology, Anselmo Marini Rehabilitation Institut, Professor of Neurology, School of Medicine, University of Morón, Associate Professor of Neurology, School of Medicine, UBA, Buenos Aires, Argentina.
Received: August 25, 2021; Published: September 28, 2021


Tourette's syndrome (TS) is a complex neuro-psychiatric disorder that manifests itself in childhood or adolescence. It is characterized by motor and vocal tics, present at least one year prior to the consultation and of a changing nature in number, frequency and complexity. Patients with TS may manifest psychiatric comorbidities: 1-attention deficit hyperactivity syndrome (ADHD), 2-obsessive-compulsive disorders (OCD), 3-impulse control disorders (ICD), 4-anxiety, 5-depression or 6-self-aggressive behaviors, which can affect their personal, social and work life. Some patients with TS progress to a severe and malignant clinical form, which generates disability, usually refractory to medical treatment. In the course of life, motor and vocal tics diminish or disappear with persistence of neuro-psychiatric manifestations. The pathophysiology of TS is unknown, although serotonergic and dopaminergic cortico-strio-pale-thalamic-cortical circuits are postulated, the involvement of which justifies the motor (tics) and behavioral manifestations. Treatment strategies vary depending on the type and degree of severity of symptoms. Treatment must be adapted to the needs and objectives of the individual patient and with respect to her family environment. Patients should be educated about the condition and, if possible, participate in behavioral therapy targeting tics and comorbidities. Various drugs, alpha adrenergic agonists, topiramate, and mono-amine transport inhibitors, are used as first-line therapies in patients with tics refractory to behavior therapy. Botulinum toxin injections are indicated in patients with severe focal tics. Typical or atypical antipsychotics (fluphenazine, aripiprazole, risperidone, and ziprasidone) are another treatment option. These generally effective medications carry the risk of metabolic syndrome, Parkinsonism, tardive dyskinesias, or other side effects. Clinical trials with ecopipam, a D1 antagonist, are promising. Patients with tics refractory to conventional treatment are candidates for neurosurgical treatment. Injury neurosurgery not exempt from sequelae is currently in disuse. Instead, deep brain stimulation surgery has been tried. The Tourette Syndrome Association and the European Society for the Study of Tourette Syndrome have published guidelines that establish the criteria for the selection of patients who are candidates for DBS. DBS constitutes a programmable and reversible modality of neuromodulation on associative or limbic circuits within the basal ganglia and has been used to treat severe forms of TS. Preliminary results of DBS at the level of associative and/or limbic parts of the striatum, thalamus and/or the pallidum in patients with TS, demonstrated a clear decrease in the severity of tics and self-injurious behaviour. Future studies will make it possible to establish the impact of DBS in the motor sphere and in associated neuro-psychiatric comorbidities. In the present work, the clinical manifestations and the various medical and/or surgical treatment options currently available are reviewed.

Keywords: Tourette; Tics; Cognitive Behavioral Therapy; Drug Therapy; Deep Brain Stimulation


  1. Jankovic J. “Tourette's syndrome”. New England Journal of Medicine16 (2001): 1184-1192.
  2. Roger Kurlan MD. “Tourette’s Syndrome”. New England Journal of Medicine 363 (2010): 2332-2338.
  3. J Jankovic and R Kurlan. “Tourette syndrome: evolving concepts”. Movement Disorders6 (2011): 1149-1156.
  4. American Psychiatric Association DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5 (5th edition). American Psychiatric Publishing, Inc (2013).
  5. Tamara Pringsheim. “My Approach to Tic Disorders Syllabus”. University of Calgary. Parkinson Disease and Movement Disorders Congress (2020).
  6. Davide Martino and Tamara M Pringsheim. “Tourette syndrome and other chronic tic disorders: an update on clinical management”. Expert Review of Neurotherapeutics2 (2017): 125-137.
  7. Knight T., et al. “Prevalence of tic disorders: a systematic review and metaanalysis”. Pediatric Neurology2 (2012): 77-90.
  8. Hirschtritt ME., et al. “Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome”. JAMA Psychiatry4 (2015): 325-333.
  9. Yang J., et al. “The prevalence of diagnosed tourette syndrome in Canada: A national population-based study”. Movement Disorders11 (2016): 1658-1663.
  10. Wolicki SB., et al. “Children with Tourette Syndrome in the United States: Parent-Reported Diagnosis, Co-Occurring Disorders, Severity, and Influence of Activities on Tics”. Journal of Developmental and Behavioral Pediatrics6 (2019): 407-414.
  11. Groth C., et al. “Course of Tourette Syndrome and Comorbidities in a Large Prospective Clinical Study”. Journal of the American Academy of Child and Adolescent Psychiatry 4 (2017): 304-312.
  12. Groth C., et al. “Predictors of the Clinical Course of Tourette Syndrome: A Longitudinal Study”. Journal of Child Neurology 14 (2019): 913-921.
  13. Pringsheim T., et al. “Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders”. Neurology19 (2019): 896-906.
  14. Pringsheim T., et al. “Comprehensive systematic reviewsummary: Treatment of tics in people with Tourette syndrome and chronic tic disorders”. Neurology 19 (2019): 907-915.
  15. Andrew Billnitzer and Joseph Jankovic. “Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments”. Neurotherapeutics4 (2020): 1681-1693.
  16. Mary F Seideman and Travis A Seideman. “A Review of the Current Treatment of Tourette Syndrome”. Journal of Pediatric Pharmacology and Therapeutics5 (2020): 401-412.
  17. Roessner V y col. “European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment”. European Child and Adolescent Psychiatry4 (2011): 173-196.
  18. Nicholas Cothros Alex Medina and Tamara Pringsheim. “Current pharmacotherapy for tic disorders”. Expert Opinion on Pharmacotherapy 5 (2020): 567-580.
  19. Pringsheim T., et al. “Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy”. The Canadian Journal of Psychiatry3 (2012): 133-143.
  20. Neuner I., et al. “Effectineness of aripiprazole in the treatment of adult Tourette patients up to 56 months”. Human Psychopharmacology4 (2012): 364-369.
  21. Wenzel C., et al. “Aripiprazole for the treatment of Tourette syndrome<. A case series of 100 patients”. Journal of Clinical Psychopharmacology4 (2012): 548-550.
  22. Swain JE., et al. “Tourette syndrome and tic disorders: a decade of progress”. Journal of the American Academy of Child and Adolescent Psychiatry8 (2007): 947-968.
  23. Hedderick EF., et al. “Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome”. Pediatric Neurology6 (2009): 420-425.
  24. Jankovic J., et al. “A randomised, doublé-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome”. Journal of Neurology, Neurosurgery, and Psychiatry1 (2010): 70-73.
  25. Muller-Vahl KR. “Treatment of Tourette syndrome with cannabinoids”. Behavioural Neurology1 (2013): 119-124.
  26. Singer HS., et al. “Baclofen treatment in Tourette syndrome. A double-blind, placebo-controlled, crossover trial”. Neurology5 (2001): 599-604.
  27. Sanberg PR., et al. “Nicotine potentiation of haloperidol-induced catalepsy: Striatal mechanisms”. Pharmacology Biochemistry and Behavior2 (1993): 303-307.
  28. Hughes JR., et al. “Recent advances in the pharmacotherapy of smoking”. JAMA: The Journal of the American Medical Association 1 (1999): 72-76.
  29. Marras C., et al. “Botulinunm toxin for simple motor tics: a randomized, doublé-blind, control clinical trial”. Neurology5 (2001): 605-610.
  30. Gilbert Donald L., et al. “A D1 Receptor Antagonist, Ecopipam, for Treatment of Tics in Tourette Syndrome”. Clinical Neuropharmacology 1 (2014): 26-30.
  31. Jankovic J and Beach J. “Long-term effects of tetrabenazine in hyperkinetic movement disorders”. Neurology2 (1997): 358-362.
  32. Kenney C and Jankovic J. “Tetrabenazine in the treatment of hyperkinetic movement disorders”. Expert Review of Neurotherapeutics 1 (2006): 7-17.
  33. Ondo WG., et al. “Comparison of weight gain in treatments for Tourette syndrome: tetrabenazine versus neuroleptic drugs”. Journal of Child Neurology4 (2008): 435-437.
  34. Silay Y and Jankovic J. “Emerging drugs in Tourette syndrome”. Expert Opinion on Emerging Drugs2 (2005): 365-380.
  35. Principles and Practice of movement disorders. Stanley Fahn, Joseph Jankovic, Mark Hallett. Edition. Elsevier. 2nd edition (2011): 330.
  36. Hartman Andreas. “Parkinson disease and other movement disorders”. Wolters Baumann VU University Press. Eric Wolters, Christian Baumann edition. Chapter 31 (2014): 561-576.
  37. Azrin NH., et al. “A method of eliminating nervous habits and tics”. Behaviour Research and Therapy4 (1973): 619-628.
  38. Piacentini J., et al. “Behavior therapy for children with Tourette disorder: a randomized controlled trial”. JAMA: The Journal of the American Medical Association19 (2010): 1929-1937.
  39. Wilhelm S., et al. “Randomized trial of behavior therapy for adults with Tourette syndrome”. The Archives of General Psychiatry8 (2012): 795-803.
  40. Verdellen Keijsers GP., et al. “Exposure with response prevention versus habit reversal in Tourette syndrome: a controlled study”. Behaviour Research and Therapy5 (2004): 501-511.
  41. Robertson MM and Eapen V. “Pharmacologic controversy of CNS stimulants in Gilles de la Tourette’s syndrome”. Clinical Neuropharmacology5 (1992): 408-425.
  42. Jankovic J. “Deprenyl in attention deficit associated with Tourette’s syndrome”. Archives of Neurology3 (1993): 286-288.
  43. Kelsey DK., et al. “Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial”. Pediatrics1 (2004): e1-e8.
  44. Spencer TJ., et al. “Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome”. Journal of Attention Disorders4 (2008): 470-481.
  45. March JS., et al. “Cognitive-behavioral psychotherapy for pediatric obsessive-compulsive disorder”. Journal of Child Psychology and Psychiatry1 (2001): 8-18.
  46. Pediatric OCD Treatment Study (POTS) Team. “Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Pediatric OCD Treatment Study (POTS) randomized controlled trial”. JAMA: The Journal of the American Medical Association16 (2004): 1969-1976.
  47. Flament MF and Bisserbe JC. “Pharmacologic treatment of obsessive-compulsive disorder: Comparative studies”. The Journal of Clinical Psychiatry2 (1997): 18-22.
  48. Bruun RD and Budman CL. “Paroxetine treatment of episodic rages associated with Tourette’s disorder”. The Journal of Clinical Psychiatry11 (1998): 581-584.
  49. Goodman WK., et al. “Biologic approaches to treatment-refractory obsessive-compulsive disorder”. Psychiatric Annals11 (1998): 641-649.
  50. Vandewalle V., et al. “Stereotactic treatment of Gilles de la Tourette syndrome by high frequency stimulation of the thalamus”. Lancet 3 (1999): 724.
  51. Maciunas RJ., et al. “Prospective randomized double-blind trial of bilateral thalamic deep brain stimulation in adults with Tourette syndrome”. Journal of Neurosurgery5 (2007): 1004-1014.
  52. Bajwa RJ., et al. “Deep brain stimulation in Tourette’s syndrome”. Movement Disorders 22 (2007): 1346-1350.
  53. Servello D., et al. “Deep brain stimulation in 18 patients with severe Gilles de la Tourette syndrome refractory to treatment: the surgery and stimulation”. Journal of Neurology, Neurosurgery, and Psychiatry2 (2008): 136-142.
  54. Porta M., et al. “Thalamic deep brain stimulation for treatment-refractory Tourette syndrome: two-year outcome”. Neurology 17 (2009): 1375-1380.
  55. Ackermans L., et al. “Doubleblind clinical trial of thalamic stimulation in patients with Tourette syndrome”. Brain 134 (2011): 832-844.
  56. Savica R., et al. “Deep brain stimulation in Tourette syndrome: a description of 3 patients with excellent outcome”. Mayo Clinic Proceedings 1 (2012): 59-62.
  57. Van Der Linden C., et al. “Successful treatment of tics with bilateral internal pallidum stimulation in a 27-year old male patient with Gilles de la Tourette’s syndrome”. Movement Disorders 17 (2002): S343.
  58. Diederich NJ., et al. “Efficient internal pallidal stimulation in Gilles de la Tourette syndrome: a case report”. Movement Disorders 11 (2005): 1496-1520.
  59. Dehning S., et al. “Therapy-refractory Tourette syndrome: beneficial outcome with globus pallidus internus deep brain stimulation”. Movement Disorders 9 (2008): 1300-1302.
  60. Dehning S., et al. “Globus pallidus internus-deep brain stimulation in Tourette’s syndrome: can clinical symptoms predict response”. Movement Disorders 13 (2011): 2440-2441.
  61. Welter ML., et al. “Internal pallidal and thalamic stimulation in patients with Tourette syndrome”. Acta Neurologica Scandinavica7 (2008): 952-957.
  62. Ackermans L., et al. “Deep brain stimulation in Tourette’s syndrome: Two targets?” Movement Disorders5 (2006): 709-713.
  63. Filho OV., et al. “Bilateral globus pallidus externus deep brain stimulation for the treatment of Tourette syndrome: an ongoing prospective controlled study”. Stereotactic and Functional Neurosurgery 1 (2007): 42-43.
  64. Martinez-Fernandez R., et al. “Deep brain stimulation for Gilles de la Tourette syndrome: a case series targeting sub-regions of the globus pallidus internus”. Movement Disorders 10 (2011): 1922-1930.
  65. Milan MK., et al. “Deep brain stimulation for obsessive compulsive disorder: past, present, and future”. Neurosurgical Focus 2 (2010): E10.
  66. Flaherty AW., et al. “Deep brain stimulation of the anterior internal capsule for the treatment of Tourette syndrome: technical case report”. Neurosurgery 4 (2005): E403.
  67. Shields DC., et al. “Microelectrode-guided deep brain stimulation for Tourette syndrome: within-subject comparison of different stimulation sites”. Stereotactic and Functional Neurosurgery2 (2008): 87-91.
  68. Kuhn J., et al. “Deep brain stimulation of the nucleus accumbens and the internal capsule in therapeutically refractory Tourette-syndrome”. Journal of Neurology7 (2007): 963-965.
  69. Neuner I., et al. “Deep brain stimulation in the nucleus accumbens for intractable Tourette’s syndrome: follow-up report of 36 months”. Biological Psychiatry4 (2009): e5-e6.
  70. Burdick A., et al. “Lack of benefit of accumbens/capsular deep brain stimulation in a patient with both tics and obsessive-compulsive disorder”. Neurocase 16 (2010): 321-330.
  71. Alejandro S Galati., et al. “Bilateral DBS of the Antero-Medial Gpi and Gpe for the Treatment of Tourette Syndrome. Case Report”. EC Neurology9 (2019): 874-881.
  72. Mink JW., et al. “Patients selection and assessment recommendations for deep brain stimulation in Tourette syndrome”. Movement Disorders11 (2006): 1831-1838.
  73. Scahili I., et al. “Contemporary assessment and pharmacotherapy of Tourette syndrome”.
  74. Claude Schofield., et al. TAA (2021).
  75. Sacristan HE., et al. “The Essentials in Deep Brain Stimulation”. EC Neurology7 (2020): 76-90.
  76. Bloch MH., et al. “Predictors of early adult outcomes in pediatric onset obsessive-compulsive disorder”. Pediatrics4 (2009): 1085-1093.
Citation: Sacristán HE., et al. “The Essentials in Tourette Syndrome”. EC Neurology 13.10 (2021): 91-110.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

January Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the November issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before February 13, 2023.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.